UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Agilent Technologies, Inc. (NYSE:A - Free Report) by 9.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,231,981 shares of the medical research company's stock after buying an additional 283,445 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 1.13% of Agilent Technologies worth $434,184,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of A. Sienna Gestion grew its position in shares of Agilent Technologies by 29.8% in the fourth quarter. Sienna Gestion now owns 78,445 shares of the medical research company's stock valued at $10,537,000 after purchasing an additional 17,991 shares during the last quarter. Sequoia Financial Advisors LLC grew its position in shares of Agilent Technologies by 8.5% in the fourth quarter. Sequoia Financial Advisors LLC now owns 33,898 shares of the medical research company's stock valued at $4,554,000 after purchasing an additional 2,664 shares during the last quarter. Prudential PLC grew its position in shares of Agilent Technologies by 16.0% in the fourth quarter. Prudential PLC now owns 73,273 shares of the medical research company's stock valued at $9,843,000 after purchasing an additional 10,128 shares during the last quarter. Commonwealth Equity Services LLC grew its position in shares of Agilent Technologies by 9.8% in the fourth quarter. Commonwealth Equity Services LLC now owns 43,862 shares of the medical research company's stock valued at $5,892,000 after purchasing an additional 3,915 shares during the last quarter. Finally, Daiwa Securities Group Inc. grew its position in shares of Agilent Technologies by 16.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 49,288 shares of the medical research company's stock valued at $6,621,000 after purchasing an additional 6,802 shares during the last quarter.
Insider Buying and Selling at Agilent Technologies
In other news, Director Daniel K. Podolsky sold 1,819 shares of the stock in a transaction on Monday, March 31st. The stock was sold at an average price of $116.46, for a total value of $211,840.74. Following the completion of the transaction, the director now directly owns 35,737 shares in the company, valued at approximately $4,161,931.02. This represents a 4.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Rodney Gonsalves sold 1,908 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $121.98, for a total value of $232,737.84. Following the completion of the transaction, the vice president now owns 21,786 shares of the company's stock, valued at $2,657,456.28. The trade was a 8.05% decrease in their ownership of the stock. The disclosure for this sale can be found here.
Analyst Ratings Changes
Several equities analysts have recently commented on A shares. Jefferies Financial Group decreased their target price on Agilent Technologies from $135.00 to $116.00 and set a "hold" rating on the stock in a research report on Monday, April 21st. Robert W. Baird reduced their price target on Agilent Technologies from $159.00 to $140.00 and set an "outperform" rating on the stock in a research report on Thursday. TD Cowen increased their price target on Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research report on Thursday, April 10th. Barclays reduced their price target on Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Finally, Wells Fargo & Company reduced their price target on Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating on the stock in a research report on Thursday, April 17th. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, Agilent Technologies presently has an average rating of "Moderate Buy" and a consensus price target of $141.42.
View Our Latest Analysis on A
Agilent Technologies Price Performance
Shares of A stock traded down $1.07 during trading hours on Friday, reaching $108.61. The company's stock had a trading volume of 1,690,973 shares, compared to its average volume of 1,924,993. The firm's 50 day simple moving average is $109.43 and its 200-day simple moving average is $127.33. The company has a market capitalization of $30.97 billion, a price-to-earnings ratio of 24.97, a PEG ratio of 3.07 and a beta of 1.27. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $153.84. The company has a quick ratio of 1.66, a current ratio of 2.20 and a debt-to-equity ratio of 0.56.
Agilent Technologies (NYSE:A - Get Free Report) last issued its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, beating analysts' consensus estimates of $1.27 by $0.04. The firm had revenue of $1.68 billion for the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. Sell-side analysts forecast that Agilent Technologies, Inc. will post 5.54 earnings per share for the current year.
Agilent Technologies Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 23rd. Shareholders of record on Tuesday, July 1st will be issued a $0.248 dividend. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date of this dividend is Tuesday, July 1st. Agilent Technologies's dividend payout ratio is presently 22.76%.
Agilent Technologies Company Profile
(
Free Report)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Further Reading
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
